today announced that the U.S. Foodand DrugAdministration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
Simply sign up to the Artificial intelligence myFT Digest -- delivered directly to your inbox. The writer is executive director of the Aspen Strategy Group and a visiting fellow at Stanford ...
Issue: Whether a manufacturer may file a petition for review in a circuit (other than the U.S. Court of Appeals for the District of Columbia Circuit) where it neither resides nor has its principal ...